| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2012.11.016 |
| P698 | PubMed publication ID | 23159460 |
| P50 | author | Polly Roy | Q20054092 |
| Stéphan Zientara | Q37341576 | ||
| Cyril Viarouge | Q37342096 | ||
| Corinne Sailleau | Q88047432 | ||
| Emmanuel Breard | Q89048303 | ||
| Alexandra Desprat | Q121336000 | ||
| P2093 | author name string | Eric Dubois | |
| Richard Thiéry | |||
| Meredith Stewart | |||
| P2860 | cites work | Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 |
| Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep | Q27315250 | ||
| Bluetongue in Europe: past, present and future | Q31078762 | ||
| Bluetongue in Europe and the Mediterranean Basin: history of occurrence prior to 2006. | Q31162311 | ||
| Multigene expression of protein complexes by iterative modification of genomic Bacmid DNA | Q33499534 | ||
| Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus | Q34238676 | ||
| Culicoides and the emergence of bluetongue virus in northern Europe | Q37418451 | ||
| Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference | Q37919891 | ||
| Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. | Q39490926 | ||
| Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus. | Q39490935 | ||
| Evaluation of interferences between dengue vaccine serotypes in a monkey model. | Q39887927 | ||
| Bluetongue in Belgium, 2006. | Q40123163 | ||
| Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. | Q40390724 | ||
| Field observations during the bluetongue serotype 8 epidemic in 2006. I. Detection of first outbreaks and clinical signs in sheep and cattle in Belgium, France and the Netherlands | Q40414486 | ||
| Vaccines against bluetongue in Europe. | Q40440398 | ||
| Genetically engineered particulate virus-like structures and their use as vaccine delivery systems | Q41259554 | ||
| Immunologic interference from sequential administration of live attenuated alphavirus vaccines. | Q44851631 | ||
| A side effect of decreased fertility associated with vaccination against bluetongue virus serotype 8 in Holstein dairy cows. | Q45365692 | ||
| Bluetongue virus RNA detection by RT-qPCR in blood samples of sheep vaccinated with a commercially available inactivated BTV-8 vaccine | Q45374776 | ||
| Toggenburg Orbivirus, a new bluetongue virus: initial detection, first observations in field and experimental infection of goats and sheep | Q45386063 | ||
| A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. | Q45394011 | ||
| Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants | Q45401393 | ||
| Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. | Q45782124 | ||
| Protective efficacy of virus-like particles for bluetongue disease | Q45880426 | ||
| Possible adverse reactions in sheep after vaccination with inactivated BTV vaccines | Q48167903 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bluetongue virus | Q883122 |
| P304 | page(s) | 553-558 | |
| P577 | publication date | 2012-11-14 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen | |
| P478 | volume | 31 |
| Q38735004 | A review of potential bluetongue virus vaccine strategies |
| Q46240566 | Bluetongue virus serotype 27: Experimental infection of goats, sheep and cattle with three BTV-27 variants reveal atypical characteristics and likely direct contact transmission BTV-27 between goats. |
| Q47159026 | Bluetongue: control, surveillance and safe movement of animals |
| Q59359646 | CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR Mice |
| Q31148174 | Culicoides midge bites modulate the host response and impact on bluetongue virus infection in sheep |
| Q37346447 | Design of virus-based nanomaterials for medicine, biotechnology, and energy |
| Q41637897 | Detection, discrimination and quantitation of 22 bluetongue virus serotypes using real-time RT-PCR with TaqMan MGB probes |
| Q34687464 | Plant-based vaccines against viruses. |
| Q91651879 | Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness |
| Q92543295 | Potential of Using Capripoxvirus Vectored Vaccines Against Arboviruses in Sheep, Goats, and Cattle |
| Q91872284 | Prospects of Next-Generation Vaccines for Bluetongue |
| Q37123514 | Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep |
| Q38167166 | Recombinant vaccines against bluetongue virus |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q41035291 | Synthesis of empty african horse sickness virus particles. |
| Q38603912 | The application of virus-like particles as vaccines and biological vehicles |
| Q38243160 | Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens |
Search more.